Product Code: BHP0678SB
“Global Molecular Diagnostics Market to Reach $24,228.0 Million by 2031.”
Market Report Coverage - Molecular Diagnostics
Market Segmentation
- Products (Kits and Consumables, Systems, Software and Other Products)
- Testing Location (Laboratory Testing and Point-of-Care (POC) Testing)
- Application (Core Molecular Diagnostics, Reproductive Genetics, Companion Diagnostics (CDx), Liquid Biopsy, and Others)
- Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing, Isothermal Nucleic Acid Amplification Technology (INAAT), Microarray, In-situ Hybridization (ISH), Immunohistochemistry (IHC) and Other Technologies)
- End User (Hospitals, Diagnostics Centers, Out-Patient Clinics/General Practitioners, Research Laboratories, and Other End Users)
Regional Segmentation
- North America: U.S., Canada
- Europe: Germany, France, Italy, U.K., Spain, and Rest-of- Europe
- Asia-Pacific: Japan, China, India, Australia, Singapore, and Rest-of-Asia-Pacific
- Latin America: Brazil, Mexico, Rest-of-Latin America
Market Growth Drivers
- A Highly Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
- Growth in the Biomarker Identification Market and Advancements in Molecular Techniques
- Increase in Awareness and Acceptance of Personalized Medicines on a Global Level
- Significant External Funding for Executing Research and Development Exercises
Market Challenges
- Uncertain Reimbursement Scenario
- Lack of High-Complexity Testing Centers
- Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
Market Opportunities
- Massive Scope for Adoption of Molecular Diagnostics in Emerging Nations
- Rise of Next-Generation Ultrasensitive Molecular Diagnostics
Key Companies Profiled
Abbott, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), bioMerieux SA, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche Ltd, Guardant Health, HTG Molecular Diagnostics, Inc., Illumina, Inc., Invivoscribe, Inc., ICON plc, LungLife AI, Inc., QIAGEN, QuantuMDx Group Ltd., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc.
Key Questions Answered in this Report:
- How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
- What are the major market drivers, challenges, and opportunities in the global molecular diagnostics market?
- What are the underlying structures resulting in the emerging trends within the global molecular diagnostics market?
- How is each segment of the global molecular diagnostics market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
- What are the key developmental strategies implemented by the major players to sustain in the competitive market?
- What are the key regulatory implications in developed and developing regions for molecular diagnostics?
- Who are the leading players with significant offerings to the global molecular diagnostics market? What is the current market dominance for each of these leading players?
- What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which molecular diagnostic product type has the most promising growth?
- What are the key applications in the global molecular diagnostics market? What are the major segments of these applications? What technologies are dominating these application segments?
- What are the major technologies that are employed in the global molecular diagnostics market? Which is the dominating technology?
- Who are the primary end-users of the global molecular diagnostics market? Which is the fastest-growing end-user segment in the global molecular diagnostics market?
- Who are the key manufacturers in the global molecular diagnostics market, and what are their contributions? Also, what is the growth potential of each major molecular diagnostics manufacturer?
- What is the scope of the global molecular diagnostics market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which molecular diagnostics application and end user dominate these regions?
- What are the emerging trends in the global molecular diagnostics market? How are these trends revolutionizing the diagnostic procedure?
- Which technologies are anticipated to break through the current molecular diagnostic regime?
- Which companies are anticipated to be highly disruptive in the future and why?
- What are the regulatory procedures that are required to unify the approval process for emerging molecular diagnostics? How will these enhance the reimbursement scenario?
- What are the gaps in regularizing optimum molecular diagnostic adoption in regular healthcare routines? How are these gaps being tackled?
Market Overview
Diagnostic tests provide critical insights at every stage of medical care - right from the genetic tests providing information about personalized cancer treatment to the microbial culture identifying accurate antibiotics against an infection. The importance of diagnostic tests throughout the entire procedure (i.e., prevention, detection, diagnosis, treatment, and successful management of health conditions) of treating an individual for a particular disease is as consequential as the treatment itself. It has been subjected to extensive research for further refinement of the same.
Our healthcare experts have found the molecular diagnostics market to be one of the stable markets, and the global market is predicted to grow from $10,914.6 million in 2020 to $24,228.0 million in 2031 and is expected to grow with a CAGR of 7.38% during the forecast period 2021-2031.
Factors fueling the growth of the market include a highly increasing prevalence of infectious diseases and various types of cancer, an increase in awareness and acceptance of personalized medicines on a global level, and significant external funding for executing research and development exercises. Despite rapid advanced industry growth, several key issues need to be addressed to facilitate future growth. Uncertain reimbursement scenarios, lack of high-complexity testing centers, and complex regulatory frameworks delaying the approval of new molecular diagnostic tests are hampering the market growth. Further, some of the opportunities, such as massive scope for the adoption of molecular diagnostics in emerging nations and the rise of next-generation ultrasensitive molecular diagnostics and novel revenue streams, provide growth to the market.
Within the research report, the market has been segmented based on product, testing location, application, technology, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the prevalence of infectious diseases and various types of cancer globally has created a buzz among companies to invest in advanced technologies such as molecular diagnostics.
Based on region, North America holds the largest share, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific and Europe regions are anticipated to grow at the fastest CAGR during the forecast period.
Table of Contents
1. Markets
- 1.1. Product Definition
- 1.1.1. Definitions
- 1.1.2. Inclusion and Exclusion
- 1.2. Market Overview
- 1.3. Historical Perspective
- 1.4. Significant Technologies
- 1.5. Classification of Molecular Diagnostics
- 1.6. Global Footprint
- 1.7. Global Molecular Diagnostics Market Size and Forecast - Realistic, Optimistic, and Conservative Growth Scenario
- 1.7.1. Realistic Growth Scenario
- 1.7.2. Conservative Growth Scenario
- 1.8. Future Potential
- 1.8.1. Optimistic Growth Scenario
- 1.9. Market Dynamics
- 1.9.1. Impact Analysis
- 1.9.2. Market Drivers
- 1.9.2.1. A Highly Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
- 1.9.2.2. Growth in the Biomarker Identification Market and Advancements in Molecular Techniques
- 1.9.2.3. Increase in Awareness and Acceptance of Personalized Medicines on a Global Level
- 1.9.2.4. Significant External Funding for Executing Research and Development Exercises
- 1.9.3. Market Restraints
- 1.9.3.1. Uncertain Reimbursement Scenario
- 1.9.3.2. Lack of High-Complexity Testing Centers
- 1.9.3.3. Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
- 1.9.4. Market Opportunities
- 1.9.4.1. Massive Scope for Adoption of Molecular Diagnostics in Emerging Nations
- 1.9.4.2. Rise of Next-Generation Ultrasensitive Molecular Diagnostics
- 1.9.4.3. Novel Revenue Streams
- 1.1. COVID-19 Impact on Global Molecular Diagnostics Market
- 1.10.1. Impact on Market Size
- 1.10.2. Impact on Molecular Diagnostic Practices
- 1.11. Competitive Landscape
- 1.11.1. Acquisitions
- 1.11.2. Synergistic Activities
- 1.11.3. Product Launches and Upgradations
- 1.11.4. Business Expansion
- 1.11.5. Market Share Analysis, by Company
- 1.11.6. Growth Share Analysis, by Technology
- 1.12. Industry Insights
- 1.12.1. Legal Requirements and Framework in the U.S.
- 1.12.2. FDA Regulations
- 1.12.3. Legal Requirements and Framework in Europe
- 1.12.3.1. U.K.
- 1.12.3.2. Germany
- 1.12.4. Legal Requirements and Framework in Asia-Pacific
- 1.12.4.1. China
- 1.12.4.2. Japan
- 1.12.4.2.1. Pharmaceuticals and Medical Devices Agency (PMDA)
- 1.12.4.2.2. Ministry of Health, Labour, and Welfare (MHLW)
- 1.12.4.3. India
- 1.13. Patent Analysis
- 1.13.1. Patent Filing Trend
2. Products
- 2.1. Overview
- 2.1.1. Systems
- 2.1.2. Kits and Consumables
- 2.1.3. Software and Other Products
3. Testing Location
- 3.1. Overview
- 3.1.1. Laboratory Testing
- 3.1.2. Point-of-Care Testing
4. Technology
- 4.1. Overview
- 4.1.1. Polymerase Chain Reaction (PCR)
- 4.1.2. Next-Generation Sequencing
- 4.1.3. Isothermal Nucleic Acid Amplification Technology (INAAT)
- 4.1.4. Microarray
- 4.1.5. In-Situ Hybridization (ISH)
- 4.1.6. Immunohistochemistry (IHC)
- 4.1.7. Other Technologies
5. Application
- 5.1. Overview
- 5.1.1. Core Molecular Diagnostics
- 5.1.1.1. Infectious Disease
- 5.1.1.1.1. Respiratory Infections
- 5.1.1.1.1.1. Influenza A and B
- 5.1.1.1.1.2. COVID-19 Infections
- 5.1.1.1.1.3. Respiratory Syncytial Virus
- 5.1.1.1.1.4. Mycoplasma Infections
- 5.1.1.1.1.5. Pertussis
- 5.1.1.1.1.6. Other Respiratory Infections
- 5.1.1.1.2. Sexual Transmitted Infections(STI)
- 5.1.1.1.2.1. Common Pathogens Associated with Sexually Transmitted Infection
- 5.1.1.1.2.2. Hepatitis B
- 5.1.1.1.2.3. HIV-AIDS
- 5.1.1.1.2.4. HPV
- 5.1.1.1.2.5. Herpes Simplex Virus
- 5.1.1.1.2.6. Neisseria Gonorrhoeae
- 5.1.1.1.2.7. Other STIs
- 5.1.1.2. Hereditary Genetic Testing
- 5.1.1.3. Blood Donor Screening
- 5.1.1.4. Oncology
- 5.1.1.5. Human Leukocyte Antigen (HLA) Testing
- 5.1.1.6. Other Molecular Diagnostics Applications
- 5.1.2. Reproductive Genetics
- 5.1.2.1. Carrier Screening
- 5.1.2.2. Non-Invasive Pre-Natal Testing (NIPT)
- 5.1.2.3. Pre-Implantation Genetic Testing
- 5.1.2.4. Infertility Genetic Testing
- 5.1.3. Companion Diagnostics (CDx)
- 5.1.4. Liquid Biopsy
- 5.1.5. Other Applications
6. End-User
- 6.1. Overview
- 6.1.1. Hospitals
- 6.1.1.1. Hospitals, by Respiratory Infections Molecular Diagnostics Market
- 6.1.1.1.1. Hospitals, by Influenza A and B
- 6.1.1.1.2. Hospitals, by COVID-19 Infections
- 6.1.1.1.3. Hospitals, by Respiratory Syncytial Virus
- 6.1.1.1.4. Hospitals, by Mycoplasma Infection
- 6.1.1.1.5. Hospitals, by Pertussis
- 6.1.1.1.6. Hospitals, by Other Respiratory Infections
- 6.1.1.2. Hospitals Sexually Transmitted Infections (STIs) Market
- 6.1.1.2.1. Hospitals, by Hepatitis B
- 6.1.1.2.2. Hospitals, by HIV AIDS
- 6.1.1.2.3. Hospitals, by HPV
- 6.1.1.2.4. Hospitals, by Herpes Simplex Virus(HSV)
- 6.1.1.2.5. Hospitals, by Neisseria gonorrhoeae
- 6.1.1.2.6. Hospitals, by Other STIs
- 6.1.2. Diagnostic Centers
- 6.1.2.1. Diagnostic Centers, by Respiratory Infections Molecular Diagnostics Market
- 6.1.2.1.1. Diagnostic Centers, by Influenza A and B
- 6.1.2.1.2. Diagnostic Centers, by COVID-19 Infections
- 6.1.2.1.3. Diagnostic Centers, by Respiratory Syncytial Virus
- 6.1.2.1.4. Diagnostic Centers, by Mycoplasma Infection
- 6.1.2.1.5. Diagnostic Centers, by Pertussis
- 6.1.2.1.6. Diagnostic Centers, by Other Respiratory Infections
- 6.1.2.2. Diagnostic Centers Sexually Transmitted Infections (STIs) Market
- 6.1.2.2.1. Diagnostic Centers, by Hepatitis B
- 6.1.2.2.2. Diagnostic Centers, by HIV AIDS
- 6.1.2.2.3. Diagnostic Centers, by HPV
- 6.1.2.2.4. Diagnostic Centers, by Herpes Simplex Virus(HSV)
- 6.1.2.2.5. Diagnostic Centers, by Neisseria gonorrhoeae
- 6.1.2.2.6. Diagnostic Centers, by Other STIs
- 6.1.3. Out-Patient Clinics/General Practitioners
- 6.1.3.1. Out-Patient Clinics/General Practitioners, by Respiratory Infections Molecular Diagnostics Market
- 6.1.3.1.1. Out-Patient Clinics/General Practitioners, by Influenza A and B
- 6.1.3.1.2. Out-Patient Clinics/General Practitioners, by COVID-19 Infections
- 6.1.3.1.3. Out-Patient Clinics/General Practitioners, by Respiratory Syncytial Virus
- 6.1.3.1.4. Out-Patient Clinics/General Practitioners, by Mycoplasma Infection
- 6.1.3.1.5. Out-Patient Clinics/General Practitioners, by Pertussis
- 6.1.3.1.6. Out-Patient Clinics/General Practitioners, by Other Respiratory Infections
- 6.1.3.2. Out-Patient Clinics/General Practitioners Sexually Transmitted Infections (STIs) Market
- 6.1.3.2.1. Out-Patient Clinics/General Practitioners, by Hepatitis B
- 6.1.3.2.2. Out-Patient Clinics/General Practitioners, by HIV AIDS
- 6.1.3.2.3. Out-Patient Clinics/General Practitioners, by HPV
- 6.1.3.2.4. Out-Patient Clinics/General Practitioners, by Herpes Simplex Virus(HSV)
- 6.1.3.2.5. Out-Patient Clinics/General Practitioners, by Neisseria gonorrhoeae
- 6.1.3.2.6. Out-Patient Clinics/General Practitioners, by Other STIs
- 6.1.4. Research Laboratories
- 6.1.4.1. Research Laboratories, by Respiratory Infections Molecular Diagnostics Market
- 6.1.4.1.1. Research Laboratories, by Influenza A and B
- 6.1.4.1.2. Research Laboratories, by COVID-19 Infections
- 6.1.4.1.3. Research Laboratories, by Respiratory Syncytial Virus
- 6.1.4.1.4. Research Laboratories, by Mycoplasma Infection
- 6.1.4.1.5. Research Laboratories, by Pertussis
- 6.1.4.1.6. Research Laboratories, by Other Respiratory Infections
- 6.1.4.2. Research Laboratories Sexually Transmitted Infections (STIs) Market
- 6.1.4.2.1. Research Laboratories, by Hepatitis B
- 6.1.4.2.2. Research Laboratories, by HIV AIDS
- 6.1.4.2.3. Research Laboratories, by HPV
- 6.1.4.2.4. Research Laboratories, by Herpes Simplex Virus(HSV)
- 6.1.4.2.5. Research Laboratories, by Neisseria gonorrhoeae
- 6.1.4.2.6. Research Laboratories, by Other STIs
- 6.1.5. Other End Users
7. Regions
- 7.1. Overview
- 7.2. North America
- 7.2.1. North America Molecular Diagnostics Market (by Application)
- 7.2.1.1. North America Respiratory Infections Molecular Diagnostics Market
- 7.2.1.1.1. North America, by Influenza A and B
- 7.2.1.1.2. North America, by COVID-19 Infections
- 7.2.1.1.3. North America, by Respiratory Syncytial Virus
- 7.2.1.1.4. North America, by Mycoplasma Infection
- 7.2.1.1.5. North America, by Pertussis
- 7.2.1.1.6. North America, by Other Respiratory Infections
- 7.2.1.2. North America Sexually Transmitted Infections (STIs) Market
- 7.2.1.2.1. North America, by Hepatitis B
- 7.2.1.2.2. North America, by HIV AIDS
- 7.2.1.2.3. North America, by HPV
- 7.2.1.2.4. North America, by Herpes Simplex Virus(HSV)
- 7.2.1.2.5. North America, by Neisseria gonorrhoeae
- 7.2.1.2.6. North America, by Other STIs
- 7.2.2. North America Molecular Diagnostics Market (by End User)
- 7.2.3. U.S.
- 7.2.4. Canada
- 7.3. Europe
- 7.3.1. Europe Molecular Diagnostics Market (by Application)
- 7.3.1.1. Europe Respiratory Infections Molecular Diagnostics Market
- 7.3.1.1.1. Europe, by Influenza A and B
- 7.3.1.1.2. Europe , by COVID-19 Infections
- 7.3.1.1.3. Europe, by Respiratory Syncytial Virus
- 7.3.1.1.4. Europe, by Mycoplasma Infection
- 7.3.1.1.5. Europe, by Pertussis
- 7.3.1.1.6. Europe, by Other Respiratory Infections
- 7.3.1.2. Europe Sexually Transmitted Infections (STIs) Market
- 7.3.1.2.1. Europe, by Hepatitis B
- 7.3.1.2.2. Europe, by HIV AIDS
- 7.3.1.2.3. Europe, by HPV
- 7.3.1.2.4. Europe, by Herpes Simplex Virus (HSV)
- 7.3.1.2.5. Europe, by Neisseria gonorrhoeae
- 7.3.1.2.6. Europe, by Other STIs
- 7.3.2. Europe Molecular Diagnostics Market (by End User)
- 7.3.3. Germany
- 7.3.4. U.K.
- 7.3.5. France
- 7.3.6. Italy
- 7.3.7. Spain
- 7.3.8. Rest-of-Europe
- 7.4. Asia-Pacific (APAC)
- 7.4.1. Asia-Pacific Molecular Diagnostics Market (by Application)
- 7.4.1.1. Asia-Pacific Respiratory Infections Molecular Diagnostics Market
- 7.4.1.1.1. Asia-Pacific, by Influenza A and B
- 7.4.1.1.2. Asia-Pacific , by COVID-19 Infections
- 7.4.1.1.3. Asia-Pacific, by Respiratory Syncytial Virus
- 7.4.1.1.4. Asia-Pacific, by Mycoplasma Infection
- 7.4.1.1.5. Asia-Pacific, by Pertussis
- 7.4.1.1.6. Asia-Pacific, by Other Respiratory Infections
- 7.4.1.2. Asia-Pacific Sexually Transmitted Infections (STIs) Market
- 7.4.1.2.1. Asia-Pacific, by Hepatitis B
- 7.4.1.2.2. Asia-Pacific, by HIV AIDS
- 7.4.1.2.3. Asia-Pacific, by HPV
- 7.4.1.2.4. Asia-Pacific, by Herpes Simplex Virus (HSV)
- 7.4.1.2.5. Asia-Pacific, by Neisseria gonorrhoeae
- 7.4.1.2.6. Asia-Pacific, by Other STIs
- 7.4.2. Asia-Pacific Molecular Diagnostics Market (by End User)
- 7.4.3. China
- 7.4.4. India
- 7.4.5. Japan
- 7.4.6. Australia
- 7.4.7. Singapore
- 7.4.8. Rest-of-Asia-Pacific
- 7.5. Latin America (LATAM)
- 7.5.1. Latin America Molecular Diagnostics Market (by Application)
- 7.5.1.1. Latin America Respiratory Infections Molecular Diagnostics Market
- 7.5.1.1.1. Latin America, by Influenza A and B
- 7.5.1.1.2. Latin America, by COVID-19 Infections
- 7.5.1.1.3. Latin America, by Respiratory Syncytial Virus
- 7.5.1.1.4. Latin America, by Mycoplasma Infection
- 7.5.1.1.5. Latin America, by Pertussis
- 7.5.1.1.6. Latin America, by Other Respiratory Infections
- 7.5.1.2. Latin America Sexually Transmitted Infections (STIs) Market
- 7.5.1.2.1. Latin America, by Hepatitis B
- 7.5.1.2.2. Latin America, by HIV AIDS
- 7.5.1.2.3. Latin America, by HPV
- 7.5.1.2.4. Latin America, by Herpes Simplex Virus (HSV)
- 7.5.1.2.5. Latin America, by Neisseria gonorrhoeae
- 7.5.1.2.6. Latin America, by Other STIs
- 7.5.2. Latin America Molecular Diagnostics Market (by End User)
- 7.5.3. Brazil
- 7.5.4. Mexico
- 7.5.5. Rest-of-Latin America
- 7.6. Rest-of-the-World (RoW)
- 7.6.1. Rest-of-the-World Molecular Diagnostics Market (by Application)
- 7.6.2. Rest-of-the-World Molecular Diagnostics Market (by End User)
- 7.6.2.1. Rest-of-the-World Respiratory Infections Molecular Diagnostics Market
- 7.6.2.2. Rest-of-the-World Sexually Transmitted Infections (STIs) Market
8. Company Profiles
- 8.1. Overview
- 8.2. Abbott
- 8.2.1. Company Overview
- 8.2.2. Role of Abbott in the Global Molecular Diagnostics Market
- 8.2.3. Financials
- 8.2.4. Key Insights about Financial Health of the Company
- 8.2.5. SWOT Analysis
- 8.3. Agilent Technologies, Inc.
- 8.3.1. Company Overview
- 8.3.2. Role of Agilent Technologies, Inc. in the Global Molecular Diagnostics Market
- 8.3.3. Financials
- 8.3.4. Key Insights about Financial of the Company
- 8.3.5. SWOT Analysis
- 8.4. Becton, Dickinson and Company (BD)
- 8.4.1. Company Overview
- 8.4.2. Role of Becton, Dickinson and Company (BD) in the Global Molecular Diagnostics Market
- 8.4.3. Financials
- 8.4.4. Key Insights about Financial Health of the Company
- 8.4.5. SWOT Analysis
- 8.5. bioMerieux SA
- 8.5.1. Company Overview
- 8.5.2. Role of bioMerieux SA in the Global Molecular Diagnostics Market
- 8.5.3. Financials
- 8.5.4. Key Insights about Financial Health of the Company
- 8.5.5. SWOT Analysis
- 8.6. Bio-Rad Laboratories, Inc.
- 8.6.1. Company Overview
- 8.6.2. Role of Bio-Rad Laboratories, Inc. in the Global Molecular Diagnostics Market
- 8.6.3. Financials
- 8.6.4. Key Insights about Financial Health of the Company
- 8.6.5. SWOT Analysis
- 8.7. Danaher
- 8.7.1. Company Overview
- 8.7.2. Role of Danaher in the Global Molecular Diagnostics Market
- 8.7.3. Financials
- 8.7.4. Key Insights about Financial Health of the Company
- 8.7.5. SWOT Analysis
- 8.8. F. Hoffmann-La Roche Ltd
- 8.8.1. Company Overview
- 8.8.2. Role of F. Hoffmann-La Roche Ltd in the Global Molecular Diagnostics Market
- 8.8.3. Financials
- 8.8.4. Key Insights about Financial Health of the Company
- 8.8.5. SWOT Analysis
- 8.9. Guardant Health
- 8.9.1. Company Overview
- 8.9.2. Role of Guardant Health in the Global Molecular Diagnostics Market
- 8.9.3. Financials
- 8.9.4. Key Insights about Financial Health of the Company
- 8.9.5. SWOT Analysis
- 8.1. HTG Molecular Diagnostics, Inc.
- 8.10.1. Company Overview
- 8.10.2. Role of HTG Molecular Diagnostics, Inc. in the Global Molecular Diagnostics Market
- 8.10.3. Financials
- 8.10.4. Key Insights about Financial Health of the Company
- 8.10.5. SWOT Analysis
- 8.11. Illumina, Inc.
- 8.11.1. Company Overview
- 8.11.2. Role of Illumina, Inc. in the Global Molecular Diagnostics Market
- 8.11.3. Financials
- 8.11.4. Key Insights about Financial Health of the Company
- 8.11.5. SWOT Analysis
- 8.12. Invivoscribe, Inc.
- 8.12.1. Company Overview
- 8.12.2. Role of Invivoscribe, Inc. in the Global Molecular Diagnostics Market
- 8.12.3. SWOT Analysis
- 8.13. ICON plc
- 8.13.1. Company Overview
- 8.13.2. Role of ICON plc in the Global Molecular Diagnostics Market
- 8.13.3. SWOT Analysis
- 8.14. LungLife AI, Inc.
- 8.14.1. Company Overview
- 8.14.2. Role of LungLife AI, Inc. in the Global Molecular Diagnostics Market
- 8.14.3. SWOT Analysis
- 8.15. QIAGEN
- 8.15.1. Company Overview
- 8.15.2. Role of QIAGEN in the Global Molecular Diagnostics Market
- 8.15.3. Financials
- 8.15.4. Key Insights about Financial Health of the Company
- 8.15.5. SWOT Analysis
- 8.16. QuantuMDx Group Ltd.
- 8.16.1. Company Overview
- 8.16.2. Role of QuantuMDx Group Ltd. in the Global Molecular Diagnostics Market
- 8.16.3. SWOT Analysis
- 8.17. Siemens Healthcare GmbH
- 8.17.1. Company Overview
- 8.17.2. Role of Siemens Healthcare GmbH in the Global Molecular Diagnostics Market
- 8.17.3. Financials
- 8.17.4. Key Insights about Financial Health of the Company
- 8.17.5. SWOT Analysis
- 8.18. Thermo Fisher Scientific Inc.
- 8.18.1. Company Overview
- 8.18.2. Role of Thermo Fisher Scientific Inc. in the Global Molecular Diagnostics Market
- 8.18.3. Financials
- 8.18.4. Key Insights About Financial Health of the Company
- 8.18.5. SWOT Analysis